- Home
- FTDR vs SRRK Comparison
FTDR vs SRRK Comparison
Compare FTDR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- SRRK
- Stock Information
- Founded
- FTDR 1971
- SRRK 2012
- Country
- FTDR United States
- SRRK United States
- Employees
- FTDR N/A
- SRRK N/A
- Industry
- FTDR Diversified Commercial Services
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTDR Finance
- SRRK Health Care
- Exchange
- FTDR Nasdaq
- SRRK Nasdaq
- Market Cap
- FTDR 3.6B
- SRRK 4.2B
- IPO Year
- FTDR 2018
- SRRK 2018
- Fundamental
- Price
- FTDR $57.97
- SRRK $43.07
- Analyst Decision
- FTDR Hold
- SRRK Strong Buy
- Analyst Count
- FTDR 6
- SRRK 7
- Target Price
- FTDR $46.80
- SRRK $40.43
- AVG Volume (30 Days)
- FTDR 508.7K
- SRRK 1.2M
- Earning Date
- FTDR 11-04-2024
- SRRK 11-12-2024
- Dividend Yield
- FTDR N/A
- SRRK N/A
- EPS Growth
- FTDR 42.94
- SRRK N/A
- EPS
- FTDR 3.00
- SRRK N/A
- Revenue
- FTDR $1,827,000,000.00
- SRRK N/A
- Revenue This Year
- FTDR $4.72
- SRRK N/A
- Revenue Next Year
- FTDR $4.35
- SRRK N/A
- P/E Ratio
- FTDR $19.37
- SRRK N/A
- Revenue Growth
- FTDR 4.16
- SRRK N/A
- 52 Week Low
- FTDR $29.41
- SRRK $6.76
- 52 Week High
- FTDR $60.42
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- FTDR 53.60
- SRRK 69.26
- Support Level
- FTDR $57.07
- SRRK $40.95
- Resistance Level
- FTDR $59.59
- SRRK $44.22
- Average True Range (ATR)
- FTDR 1.57
- SRRK 2.57
- MACD
- FTDR -0.33
- SRRK -0.12
- Stochastic Oscillator
- FTDR 41.53
- SRRK 73.14
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.